Development of In Vitro Endothelialised Stents - Review.
Jitsuro TsukadaP MelaM JinzakiH TsukadaT Schmitz-RodeF VogtPublished in: Stem cell reviews and reports (2021)
Endovascular treatment is prevalent as a primary treatment for coronary and peripheral arterial diseases. Although the introduction of drug-eluting stents (DES) dramatically reduced the risk of in-stent restenosis, stent thrombosis persists as an issue. Notwithstanding improvements in newer generation DES, they are yet to address the urgent clinical need to abolish the late stent complications that result from in-stent restenosis and are associated with late thrombus formation. These often lead to acute coronary syndromes with high mortality in coronary artery disease and acute limb ischemia with a high risk of limb amputation in peripheral arterial disease. Recently, a significant amount of research has focused on alternative solutions to improve stent biocompatibility by using tissue engineering. There are two types of tissue engineering endothelialisation methods: in vitro and in vivo. To date, commercially available in vivo endothelialised stents have failed to demonstrate antithrombotic or anti-stenosis efficacy in clinical trials. In contrast, the in vitro endothelialisation methods exhibit the advantage of monitoring cell type and growth prior to implantation, enabling better quality control. The present review discusses tissue-engineered candidate stents constructed by distinct in vitro endothelialisation approaches, with a particular focus on fabrication processes, including cell source selection, stent material composition, stent surface modifications, efficacy and safety evidence from in vitro and in vivo studies, and future directions.
Keyphrases
- tissue engineering
- coronary artery disease
- clinical trial
- quality control
- acute coronary syndrome
- endovascular treatment
- randomized controlled trial
- cardiovascular events
- heart failure
- stem cells
- coronary artery
- percutaneous coronary intervention
- risk factors
- intensive care unit
- type diabetes
- cardiovascular disease
- computed tomography
- coronary artery bypass grafting
- cell therapy
- atrial fibrillation
- bone marrow
- contrast enhanced
- aortic valve
- wastewater treatment
- open label
- study protocol
- electronic health record
- ejection fraction